Literature DB >> 34474474

Real-world outcomes of axicabtagene ciloleucel in adult patients with primary mediastinal B-cell lymphoma.

Jennifer L Crombie1, Loretta J Nastoupil2, Robert Redd1, Kevin Tang3, Geoffrey Shouse4, Alex F Herrera4, Victor A Chow5, Mazyar Shadman5, Omar Castaneda Puglianini6, Anna Saucier1, Caron A Jacobson1, Philippe Armand1, Gary Simmons6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34474474      PMCID： PMC8945592          DOI： 10.1182/bloodadvances.2021004880

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


× No keyword cloud information.
  15 in total

1.  Salvage chemotherapy and autologous stem cell transplantation are inferior for relapsed or refractory primary mediastinal large B-cell lymphoma compared with diffuse large B-cell lymphoma.

Authors:  John Kuruvilla; Melania Pintilie; Richard Tsang; Tracy Nagy; Armand Keating; Michael Crump
Journal:  Leuk Lymphoma       Date:  2008-07

2.  Expression of programmed cell death 1 ligand 2 (PD-L2) is a distinguishing feature of primary mediastinal (thymic) large B-cell lymphoma and associated with PDCD1LG2 copy gain.

Authors:  Min Shi; Margaretha G M Roemer; Bjoern Chapuy; Xiaoyun Liao; Heather Sun; Geraldine S Pinkus; Margaret A Shipp; Gordon J Freeman; Scott J Rodig
Journal:  Am J Surg Pathol       Date:  2014-12       Impact factor: 6.394

3.  Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.

Authors:  Michael R Green; Stefano Monti; Scott J Rodig; Przemyslaw Juszczynski; Treeve Currie; Evan O'Donnell; Bjoern Chapuy; Kunihiko Takeyama; Donna Neuberg; Todd R Golub; Jeffery L Kutok; Margaret A Shipp
Journal:  Blood       Date:  2010-07-13       Impact factor: 22.113

4.  Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.

Authors:  Sattva S Neelapu; Frederick L Locke; Nancy L Bartlett; Lazaros J Lekakis; David B Miklos; Caron A Jacobson; Ira Braunschweig; Olalekan O Oluwole; Tanya Siddiqi; Yi Lin; John M Timmerman; Patrick J Stiff; Jonathan W Friedberg; Ian W Flinn; Andre Goy; Brian T Hill; Mitchell R Smith; Abhinav Deol; Umar Farooq; Peter McSweeney; Javier Munoz; Irit Avivi; Januario E Castro; Jason R Westin; Julio C Chavez; Armin Ghobadi; Krishna V Komanduri; Ronald Levy; Eric D Jacobsen; Thomas E Witzig; Patrick Reagan; Adrian Bot; John Rossi; Lynn Navale; Yizhou Jiang; Jeff Aycock; Meg Elias; David Chang; Jeff Wiezorek; William Y Go
Journal:  N Engl J Med       Date:  2017-12-10       Impact factor: 91.245

5.  Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase II CheckMate 436 Study.

Authors:  Pier Luigi Zinzani; Armando Santoro; Giuseppe Gritti; Pauline Brice; Paul M Barr; John Kuruvilla; David Cunningham; Justin Kline; Nathalie A Johnson; Neha Mehta-Shah; Thomas Manley; Stephen Francis; Manish Sharma; Alison J Moskowitz
Journal:  J Clin Oncol       Date:  2019-08-09       Impact factor: 44.544

6.  Current concepts in the diagnosis and management of cytokine release syndrome.

Authors:  Daniel W Lee; Rebecca Gardner; David L Porter; Chrystal U Louis; Nabil Ahmed; Michael Jensen; Stephan A Grupp; Crystal L Mackall
Journal:  Blood       Date:  2014-05-29       Impact factor: 22.113

7.  Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma.

Authors:  David D W Twa; Fong Chun Chan; Susana Ben-Neriah; Bruce W Woolcock; Anja Mottok; King L Tan; Graham W Slack; Jay Gunawardana; Raymond S Lim; Andrew W McPherson; Robert Kridel; Adele Telenius; David W Scott; Kerry J Savage; Sohrab P Shah; Randy D Gascoyne; Christian Steidl
Journal:  Blood       Date:  2014-02-04       Impact factor: 22.113

8.  Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity.

Authors:  Caron A Jacobson; Bradley D Hunter; Robert Redd; Scott J Rodig; Pei-Hsuan Chen; Kyle Wright; Mikel Lipschitz; Jerome Ritz; Yusuke Kamihara; Philippe Armand; Sarah Nikiforow; Michael Rogalski; Joseph Maakaron; Samantha Jaglowski; Marcela V Maus; Yi-Bin Chen; Jeremy S Abramson; Justin Kline; Elizabeth Budde; Alex Herrera; Matthew Mei; Jonathon B Cohen; Stephen D Smith; David G Maloney; Ajay K Gopal; Matthew J Frigault; Utkarsh H Acharya
Journal:  J Clin Oncol       Date:  2020-07-15       Impact factor: 50.717

9.  Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma.

Authors:  Philippe Armand; Scott Rodig; Vladimir Melnichenko; Catherine Thieblemont; Kamal Bouabdallah; Gayane Tumyan; Muhit Özcan; Sergio Portino; Laura Fogliatto; Maria D Caballero; Jan Walewski; Zafer Gulbas; Vincent Ribrag; Beth Christian; Guilherme Fleury Perini; Gilles Salles; Jakub Svoboda; Jasmine Zain; Sanjay Patel; Pei-Hsuan Chen; Azra H Ligon; Jing Ouyang; Donna Neuberg; Robert Redd; Arkendu Chatterjee; Arun Balakumaran; Robert Orlowski; Margaret Shipp; Pier Luigi Zinzani
Journal:  J Clin Oncol       Date:  2019-10-14       Impact factor: 44.544

10.  Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma.

Authors:  Andreas Rosenwald; George Wright; Karen Leroy; Xin Yu; Philippe Gaulard; Randy D Gascoyne; Wing C Chan; Tong Zhao; Corinne Haioun; Timothy C Greiner; Dennis D Weisenburger; James C Lynch; Julie Vose; James O Armitage; Erlend B Smeland; Stein Kvaloy; Harald Holte; Jan Delabie; Elias Campo; Emili Montserrat; Armando Lopez-Guillermo; German Ott; H Konrad Muller-Hermelink; Joseph M Connors; Rita Braziel; Thomas M Grogan; Richard I Fisher; Thomas P Miller; Michael LeBlanc; Michael Chiorazzi; Hong Zhao; Liming Yang; John Powell; Wyndham H Wilson; Elaine S Jaffe; Richard Simon; Richard D Klausner; Louis M Staudt
Journal:  J Exp Med       Date:  2003-09-15       Impact factor: 14.307
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.